Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Thike AA, Cheok PY, Jara-Lazaro AR, et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2009;23:123–33.
Iqbal J, Ginsburg O, Rochon PA, et al. DIfferences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165–73.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.
Kassam F, Enright K, Dent R, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9:29–33.
Thike AA, Yong-Zheng Chong L, Cheok PY, et al. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. 2014;27:352–60.
Cheng CL, Thike AA, Tan SY, et al. Expression of FGFR1 is an independent prognostic factor in triple-negative breast cancer. Breast Cancer Res Treat. 2015;151:99–111.
Matsumoto H, Koo SL, Dent R, et al. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol. 2015.
Kanaan YM, Sampey BP, Beyene D, Esnakula AK, Naab TJ, Ricks-Santi LJ, Dasi S, Day A, Blackman KW, Frederick W, Copeland RL Sr, Gabrielson E, Dewitty RL Jr. Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease. Cancer Genomics Proteomics. 2014;11(6):279–94.
Sung H, Rosenberg PS, Chen WQ, et al. Female breast cancer incidence among Asian and Western populations: more similar than expected. J Natl Cancer Inst. 2015;107(7). https://doi.org/10.1093/jnci/djv107. Print 2015 Jul.
Leong SPL, Shen Z-Z, Liu T-J, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34:2308–24.
Bhoo-Pathy N, Yip C-H, Hartman M, et al. Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer. 2013;49:703–9.
de Bruin MA, Kwong A, Goldstein BA, et al. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. Familial Cancer. 2012;11:429–39.
Kim H, Choi DH. Distribution of BRCA1 and BRCA2 mutations in Asian patients with breast cancer. J Breast Cancer. 2013;16:357–65.
Wong ESY, Shekar S, Met-Domestici M, et al. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. Npj Genomic Medicine. 2016;1:15003.
Hwang ES, Miglioretti DL, Ballard-Barbash R, et al. Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomark Prev. 2007;16:2587–93.
Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med. 2002;347:886–94.
Khamis ZI, Sahab ZJ, Sang QX. Active roles of tumour stroma in breast cancer metastasis. Int J Breast Cancer. 2012;2012:574025.
Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392–401.
Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol. 2015;15:669–82.
Jiang H, Hegde S, Knolhoff BL, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22:851–60.
Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–27.
Lisanti MP, Sotgia F, Pestell RG, et al. Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. Cell Cycle. 2013;12:2935–6.
Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7.
Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumour-promoting cell type. Cell Cycle. 2006;5:1597–601.
Mercier I, Casimiro MC, Wang C, et al. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumour suppressor functional inactivation: implications for the response to hormonal therapy. Cancer Biol Ther. 2008;7:1212–25.
Giannoni E, Bianchini F, Masieri L, et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70:6945–56.
Erez N, Truitt M, Olson P, et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumour-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 2010;17:135–47.
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98.
Acerbi I, Cassereau L, Dean I, et al. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol. 2015;7:1120–34.
Tan WJ, Yan J, Xu S, et al. Second harmonic generation microscopy is a novel technique for differential diagnosis of breast fibroepithelial lesions. J Clin Pathol. 2015;68:1033–5.
Burke K, Brown E. The use of second harmonic generation to image the extracellular matrix during tumour progression. IntraVital. 2014;3:e984509.
Tilbury K, Campagnola PJ. Applications of second-harmonic generation imaging microscopy in ovarian and breast cancer. Perspectives Med Chem. 2015;7:21–32.
Robinson BK, Cortes E, Rice AJ, et al. Quantitative analysis of 3D extracellular matrix remodelling by pancreatic stellate cells. Biology Open. 2016;5:875–82.
Tilbury K, Campagnola PJ. Applications of second-harmonic generation imaging microscopy in ovarian and breast cancer. Perspect Med Chem. 2015;7:21–32.
Keikhosravi A, Bredfeldt JS, Sagar AK, et al. Second-harmonic generation imaging of cancer. Methods Cell Biol. 2014;123:531–46.
Birk JW, Tadros M, Moezardalan K, et al. Second harmonic generation imaging distinguishes both high-grade dysplasia and cancer from normal colonic mucosa. Dig Dis Sci. 2014;59:1529–34.
Nadiarnykh O, LaComb RB, Brewer MA, et al. Alterations of the extracellular matrix in ovarian cancer studied by Second Harmonic Generation imaging microscopy. BMC Cancer. 2010;10:94.
Bredfeldt JS, Liu Y, Conklin MW, et al. Automated quantification of aligned collagen for human breast carcinoma prognosis. J Pathol Inform. 2014;5:28.
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med. 2020;144(5):545-563. https://doi.org/10.5858/arpa.2019-0904-SA. Epub 2020 Jan 13.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett, JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-2122. https://doi.org/10.1200/JCO.2018.77.8738. Epub, 2018 May 30.
Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G, Huat Bay B, Tse GM, Iqbal J, Tan PH. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. 2014;27(3):352-60. https://doi.org/10.1038/modpathol.2013.145. Epub 2013 Aug 9.
Conklin MW, Keely PJ. Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers. Cell Adhes Migr. 2012;6(3):249–60. https://doi.org/10.4161/cam.20567 Epub 2012 May 1.
Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumour-stromal interface facilitates local invasion. BMC Med. 2006;4(1):38.
Conklin MW, Eickhoff JC, Riching KM, Pehlke CA, Eliceiri KW, Provenzano PP, Friedl A, Keely PJ. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol. 2011;178(3):1221–32. https://doi.org/10.1016/j.ajpath.2010.11.076.
Takai K, Le A, Weaver VM, Werb Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget. 2016;7(50):82889–901. https://doi.org/10.18632/oncotarget.12658.
Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumour progression. Tumour Biol. 2014;35(4):2871–82. https://doi.org/10.1007/s13277-013-1511-7 Epub 2013 Dec 15.
Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology. 2008;134:248–58. https://doi.org/10.1053/j.gastro.2007.09.034.
Yang YM, Seki E. TNFα in liver fibrosis. Curr Pathobiol Rep. 2015;3(4):253–61 Epub 2015 Sep 30.
Isabel F and Daniel CD, Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis. Front. Oncol., 2018 https://doi.org/10.3389/fonc.2018.00357.
Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, Ten Dijke IT-LIVER Consortium. TGF-β signalling and liver disease. FEBS J 2016;283(12):2219–2232. doi: https://doi.org/10.1111/febs.13665. Epub 2016 Feb 22.
Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. NASH clinical research network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65.
Widjaja AA, Singh BK, Adami E, Viswanathan S, Dong J, D’Agostino GA, Ng B, Lim WW, Tan J, Paleja BS, Tripathi M, Lim SY, Shekeran SG, Chothani SP, Rabes A, Sombetzki M, Bruinstroop E, Min LP, Sinha RA, Albani S, Yen PM, Schafer S, Cook SA. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology. 2019. doi: https://doi.org/10.1053/j.gastro.2019.05.002. [Epub ahead of print].
Anissa A. Widjaja, Brijesh K. Singh, Eleonora Adami, Sivakumar Viswanathan, Giuseppe A. D’Agostino, Jinrui Dong, Benjamin Ng, Jessie Tan, Bhairav S. Paleja, Madhulika Tripathi, Sze Yun Lim, Sonia P. Chothani, Wei Wen Lim, Anne Rabes, Martina Sombetzki, Eveline Bruinstroop, Rohit A. Sinha, Salvatore Albani, Paul M. Yen, Sebastian Schafer, Stuart A. Cook. IL-11 neutralising therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH. Gastroenterology doi: https://doi.org/10.1053/j.gastro.2019.05.002.
Ehab A. Ayaub, Anisha Dubey, Jewel Imani, Fernando Botelho, Martin R. J. Kolb, Carl D. Richards & Kjetil Ask. Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis, Scientific Reportsvolume 7, Article number: 13281 (2017).
Michitaka M, Shinya T,Naoko M, Eiko S, Hitoshi O, Atsushi M, Minoru T. Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice. Hepatology. 2018;67(1):296-312. https://doi.org/10.1002/hep.29421. Epub 2017 Nov 15.